EVALUATION OF THE EFFICACY OF COMBINED USE OF UPERIO AND SPIRONOLACTONE IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE WITH CORONAVIRUS INFECTION
Keywords:
chronic heart failure, ARNI drugs (angiotensin receptor and neprilysin inhibitors), old age, post-COVID syndrome.Abstract
The effectiveness of the combined use of drugs from the ARNI group and aldosterone antagonists in elderly patients with CHF who underwent coronovirus infection was studied. In patients of group I (main) who took Uperio 24/26 mg and spironolactone 25 mg/day, there was a significant improvement in clinical symptoms (shortness of breath, fatigue, edema), improvement in exercise tolerance, improvement in ECG and EchoCG patterns, a decrease in CHF FC occurred only in 12 (50%) patients. II (control) group who are taking ACE inhibitors, a satisfactory effect in 6 (25%) patients. And in 6 (25%) patients of the II-(control) group, destabilization of the disease was observed in the form of cardiac asthma, pulmonary edema.
Downloads
References
Azamkhonov, A. A., Nasriddinova, N. N., Maksudova, M. Kh., & Nadirova, Yu. I. (2020). STUDYING ASPECTS OF CORONARY HEART DISEASE COMPLICATED WITH CHRONIC HEART FAILURE. Student Gazette, (3-2), 66-67.
Popova E.K., Arkhipova N. S., Tomsky M.I. Frequency of arterial hypertension in the group of patients with ischemic heart disease of elderly age living in the conditions of the extreme north. Sibirskii Med Journal 2015;1:73–76
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under this license:
- Share: Copy and redistribute the material in any medium or format
- Adapt: Remix, transform, and build upon the material for any purpose, including commercially
Attribution required: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
License URL: https://creativecommons.org/licenses/by/4.0/
Authors retain copyright of their work while granting the journal first publication rights.
